Physician profile
John Lidvall
NPI 1376856559
$1,228.49
in general payments reported to CMS, 2019-2025
27 companies · $14.70 in 2025
The $14.70 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $309 · 2021: $65.53 · 2023: $53.67 · 2025: $14.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $68.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $68.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $177.42 | 2019-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $141.46 | 2019-2020 | |
| Astellas Pharma US INC | $114.88 | 2019-2020 | |
| Novo Nordisk INC | $97.10 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.15 | 2019-2020 | |
| Glaxosmithkline, LLC. | $57.29 | 2019-2020 | |
| Allergan, INC. | $57.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.09 | 2019-2020 | |
| Pfizer INC. | $45.02 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $40.37 | 2019-2020 | |
| Amgen INC. | $39.76 | 2019-2020 | |
| Boston Scientific Corporation | $38.05 | 2023 | Watchman Access System |
| Lilly USA, LLC | $35.52 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.10 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $29.89 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.74 | 2019 | |
| Amarin Pharma, INC. | $25.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $23.04 | 2019 | |
| Philips North America LLC | $19.02 | 2020 | |
| Fidia Pharma USA INC. | $17.91 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.12 | 2019 | |
| Sanofi Pasteur INC. | $16.53 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.47 | 2019 | |
| Eisai INC. | $14.68 | 2020 | |
| Aytu Biopharma, INC. | $14.31 | 2019 | |
| Shire North American Group INC | $12.39 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lidvall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.